ACAndrew C. Currie

Andrew C. Currie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew C. Currie has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    National introduction of one-anastomosis gastric bypass in the UK National Bariatric Surgery Registry: a cohort study

    by Andrew C PhD FRCS Currie, Alan Askari, Chetan Parmar, James Byrne, Ahmed R. Ahmed, Chris M. Pring, Omar A. Khan, Peter K. Small, Kamal Mahawar

    Aim: There is a paucity of evidence regarding the national introduction of newer bariatric metabolic surgery procedures. This study assessed the impact of introducing one-anastomosis gastric bypass (OAGB) in bariatric surgical practice in the UK on 30-day postoperative morbidity and early postoperative weight loss. Methods: Patients who underwent primary BMS in the UK National Bariatric Surgical Registry (2010–2019) were identified. Patient characteristics, 30-day postoperative morbidity, and 12-month total body weight loss (TBWL) were also assessed. Multivariate regression was performed for associations between 30-day postoperative morbidity and 12-month TBWL, with SG as a reference. Learning effects were assessed by factoring in the institutional OAGB caseload (0–24/25–49/50+ cases). Results: A total of 59 226 patients underwent primary BMS during the study period (RYGB, 38 434; SG, 24 702; AGB, 12 627; OAGB, 3408; and others, 276). The 30-day postoperative morbidity was lower for OAGB 1.8% (51/2802) compared to RYGB 4.2% (1391/32 853) and SG 3.4% (725/21 333) but higher than AGB 1.2% (123/9915), while on multivariate regression, OAGB was associated with reduced morbidity once the institution caseload exceeded 50 operations (OR 0.35 (95% CI: 0.22–0.56; PP<0.001). Conclusion: OAGB has been safely implemented in UK national bariatric surgery practice. It has lower reported postoperative morbidity and comparable weight loss to RYGB or SG, despite being offered to patients with more severe and complex obesity.


  • Efficacy of Nissen Sleeve Gastrectomy on Mid-term Barrett’s Esophagus Regression

    by Pierre Brinas, Saadeddine Joumaa, Andrew Currie, Mégane Boixière, Jean Christophe Valat, Marius Nedelcu, Ion Donici, Thomas Gautier, David Nocca

    Introduction Sleeve gastrectomy is the most commonly performed bariatric operation globally. The main complication is GERD. In the medium term, it can increase the incidence of Barrett’s esophagus (BE), which is a risk factor for esophageal adenocarcinoma. Following conventional sleeve gastrectomy, BE is noted in up to 16% of patients postoperatively. Recently, Nissen sleeve gastrectomy (NSG) has been shown to reduce the frequency of postoperative GERD compared to conventional sleeve gastrectomy. This study aims to evaluate the impact of NSG on the incidence and remission of BE in the long term. Material and Method This bicentric retrospective study included 692 patients who received NSG from September 2013 to July 2021. All patients underwent preoperative upper GI endoscopy and were then scheduled to receive upper GI endoscopy between 1 and 2 years and then between 3 and 5 years postoperatively. BE was systematically confirmed by biopsies. Results Seventy-four patients had endoscopic suspicion of BE, which was confirmed on 54/692 patients by histology. The BE lesions consisted of 18.5% intestinal metaplasia and 75.9% fundal metaplasia. Among these 54 patients, 38 underwent endoscopic investigation within 2 years postoperatively. The biopsies showed healed BE in 25/38 patients (64.1%). At 5 years, two patients had proven BE. Concerning the incidence of BE post NSG: 234 performed the follow-up endoscopy within 2 years. The incidence of de novo BE is nil. Conclusion The NSG is associated with healing of known BE in approximately two-thirds of patients at 2-year follow-up. This is consistent with the GERD improvement that has been shown with NSG. Graphical Abstract


  • Open Access

    Bariatric surgery provision in response to the COVID-19 pandemic: retrospective cohort study of a national registry

    by Emma Rose McGlone, Iain M. Carey, Andrew Currie, Kamal Mahawar, Richard Welbourn, Ahmed R. Ahmed, Chris Pring, Peter K. Small, Omar A. Khan


  • A Video-Based Review of Important Technical Concepts in the Nissen-Sleeve Gastrectomy

    by David Nocca, Andrew C. Currie, Saadeddine Joumaa, Pierre Brinas, Marius Nedelcu, Thomas Gautier

    Purpose The development of gastroesophageal reflux disease (GERD) is a commonly encountered scenario after sleeve gastrectomy. A recently reported technical amendment to incorporate a Nissen fundoplication is discussed in this multimedia article focussing on optimising outcomes and reducing complications. Materials and Methods An intraoperative video has been edited to demonstrate the Nissen-Sleeve Gastrectomy and important technical considerations in its technical performance. Results Gastrolysis is performed proximally from 6 cm proximal to the pylorus. Routine full mediastinal mobilisation of the oesophagus (5 cm) is completed. Cruroplasty is routinely performed. A short Nissen fundoplication is completed calibrated on a 37 French bougie and then sleeve gastrectomy is performed. Our team’s experience suggests that careful manipulation of the fundus and using reproducible measurements of the fundus are key to completing the fundoplication whilst minimising complications. A control test with mobilisation of the bougie through the wrap is recommended at the end of the procedure. Conclusion The Nissen-Sleeve Gastrectomy, as presented in this video, is safe and has good short-term efficacy outcomes. Longer term and randomised studies are ongoing.


  • Training in Bariatric Surgery

    by William J. Hawkins, Saurav Chakravartty, Andrew Currie


  • Top Cited Papers
    Open Access

    Prevalence of Overweight and Obesity in France: The 2020 Obepi-Roche Study by the “Ligue Contre l’Obésité”

    by Annick Fontbonne, Andrew Currie, Patrick Tounian, Marie-Christine Picot, Olivier Foulatier, Marius Nedelcu, David Nocca

    Obepi-Roche 2020 by the “Ligue Contre l’Obésité” (League Against Obesity) estimated overweight and obesity prevalence in France. The adopted methodology was chosen to be as similar as possible to that of a series of quota-based surveys conducted every three years from 1997 to 2012 (Obepi-Roche studies). The 2020 survey was conducted online from 24th September to 5th October 2020 by the Odoxa polling institute on a sample of metropolitan French subjects aged 18 years or over. Participants (n = 9598) self-measured their height and weight according to detailed instructions. Prevalence estimates were produced for all categories of body mass index. The prevalence of excess weight was 47.3% (17.0% of subjects with obesity), with higher values in the north and east of France. When comparing these 2020 estimates to previous Obepi-Roche estimates in order to visualize trends since 1997, it appeared that overweight fluctuated around 30%, and obesity prevalence increased steadily at a rapid pace. The increase was even steeper in the youngest age groups and for severe and complex obesity. Given the slightly different methodologies between the 1997–2012 studies and the 2020 survey, the worrying trends in obesity prevalence since 1997 must be confirmed, calling for a reedition of the Obepi-Roche series.


  • Bariatric‐metabolic surgery for NHS patients with type 2 diabetes in the United Kingdom National Bariatric Surgery Registry

    by Andrew Currie, Roel Bolckmans, Alan Askari, James Byrne, Ahmed R. Ahmed, Rachel L. Batterham, Kamal Mahawar, Alexander Dimitri Miras, Chris M. Pring, Peter K. Small, et al.

    Aim: Bariatric‐metabolic surgery is approved by the National Institute of Health and Care Excellence (NICE) for people with severe obesity and type 2 diabetes (T2DM) (including class 1 obesity after 2014). This study analysed baseline characteristics, disease severity and operations undertaken in people with obesity and T2DM undergoing bariatric‐metabolic surgery in the UK National Health Service (NHS) compared to those without T2DM.Methods: Baseline characteristics, trends over time and operations undertaken were analysed for people undergoing primary bariatric‐metabolic surgery in the NHS using the National Bariatric Surgical Registry (NBSR) for 11 years from 2009 to 2019. Clinical practice before and after the publication of the NICE guidance (2014) was examined. Multivariate logistic regression was used to determine associations with T2DM status and the procedure undertaken.Results: 14,948/51,715 (28.9%) participants had T2DM, with 10,626 (71.1%) on oral hypoglycaemics, 4322 (28.9%) on insulin/other injectables, and with T2DM diagnosed 10+ years before surgery in 3876 (25.9%). Participants with T2DM, compared to those without T2DM, were associated with older age (p < 0.001), male sex (p < 0.001), poorer functional status (p < 0.001), dyslipidaemia (OR: 3.58 (CI: 3.39–3.79); p < 0.001), hypertension (OR: 2.32 (2.19–2.45); p < 0.001) and liver disease (OR: 1.73 (1.58–1.90); p < 0.001), but no difference in body mass index was noted. Fewer people receiving bariatric‐metabolic surgery after 2015 had T2DM (p < 0.001), although a very small percentage increase of those with class I obesity and T2DM was noted. Gastric bypass was the commonest operation overall. T2DM status was associated with selection for gastric bypass compared to sleeve gastrectomy (p < 0.001).Conclusion: NHS bariatric‐metabolic surgery is used for people with T2DM much later in the disease process when it is less effective. National guidance on bariatric‐metabolic surgery and data from multiple RCTs have had little impact on clinical practice.


  • Training in Bariatric Surgery

    by William J. Hawkins, Saurav Chakravartty, Andrew Currie

  • Obstructive sleep apnea remission following bariatric surgery: a national registry cohort study

    by Andrew C. Currie, Vasha Kaur, Iain Carey, Hussein Al-Rubaye, Kamal Mahawar, Brijesh Madhok, Peter Small, Emma Rose McGlone, Omar A. Khan


  • Network Meta-Analysis of Metabolic Surgery Procedures for the Treatment of Obesity and Diabetes

    by Andrew C. Currie, Alan Askari, Ana Fangueiro, Kamal Mahawar

    Background Metabolic surgery is part of a well-established treatment intensification strategy for obesity and its related comorbidities including type 2 diabetes (T2DM). Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG) and one-anastomosis gastric bypass (OAGB) are the most commonly performed metabolic surgeries worldwide, but comparative efficacy is uncertain. This study employed network meta-analysis to compare weight loss, T2DM remission and perioperative complications in adults between RYGB, SG and OAGB. Methods MEDLINE, EMBASE, trial registries were searched for randomised trials comparing RYGB, SG and OAGB. Study outcomes were excess weight loss (at 1, 2 and 3–5 years), trial-defined T2DM remission at any time point and perioperative complications. Results Twenty randomised controlled trials were included involving 1803 patients investigating the three metabolic surgical interventions. RYGB was the index for comparison. The excess weight loss (EWL) demonstrated minor differences at 1 and 2 years, but no differences between interventions at 3–5 years. T2DM remission was more likely to occur with either RYGB or OAGB when compared to SG. Perioperative complications were higher with RYGB when compared to either SG or OAGB. Two-way analysis of EWL and T2DM remission against the risk of perioperative complications demonstrated OAGB was the most positive on this assessment at all time points. Conclusion OAGB offers comparable metabolic control through weight loss and T2DM remission to RYGB and SG whilst minimising perioperative complications. Registration number: CRD42020199779 (https:// www.crd.york.ac.uk/PROSPERO) Graphical abstract